Fred Guerard

Fred has 20 years of leadership, strategic and commercial experience as a pharmaceutical executive. Prior to joining Graybug Vision, Fred was Worldwide Business Franchise Head of Ophthalmology, the largest Novartis Pharma business in sales. He led the integration of the global Alcon Pharma and Novartis Retina businesses and was responsible for a number of deals leading to a significant extension of Novartis’ ophthalmology pipeline, including the acquisition of Encore Vision for the topical treatment for presbyopia (2016), the in-licensing of Lubricin® ex-EU for dry eye (2017), the in-licensing of Luxturna® ex-US, a one-time gene therapy to restore functional vision in patients with biallelic mutations of the RPE65 gene from Spark Therapeutics (2018), as well as the preparation of the Xiidra® acquisition for dry eye from Takeda Pharmaceuticals (2019).

During his 20 year tenure at Novartis, he held additional leadership positions, including Global Franchise Head of Pharmaceuticals at Alcon, Country Head of United Kingdom and Ireland, Country Head and President of Australia and New Zealand, Head of Marketing and Sales for Emerging Growth Markets Region, Country Head and President of Egypt, and Cluster Head of North and West Africa. Fred holds a PharmD and a Master of Biological and Medical Sciences from the University of Rouen, France, and a Master of Marketing from the international business school HEC (Hautes Etudes Commerciales), Paris.